Valuation: Evotec

Market Cap 61Cr 70Cr 56Cr 52Cr 98Cr 6.74TCr 100.2Cr 674.4Cr 265.26Cr 3.3TCr 262.77Cr 257Cr 11TCr P/E 2026 *
-3.99x
P/E 2027 * -9.96x
Enterprise Value 65Cr 75Cr 60Cr 56Cr 104.68Cr 7.2TCr 107Cr 720.18Cr 283.26Cr 3.52TCr 280.6Cr 274.45Cr 12TCr EV / Sales 2026 *
1.09x
EV / Sales 2027 * 0.97x
Free-Float
89.91%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO - 01/05/2026
Chief Operating Officer - 01/05/2026
Director TitleAgeSince
Director/Board Member 58 19/06/2019
Director/Board Member 64 01/06/2021
Director/Board Member 43 22/06/2022
Change 5-day change 1-year change 3-year change Capi.($)
+8.33%-.--% - - 70Cr
-1.29%-3.11%-0.35%+2.64% 4.92TCr
+3.90%-0.39%+386.06%+588.97% 3.96TCr
-1.70%+4.46%+5.93%+61.54% 3.47TCr
-2.01%-0.76%+28.41%-8.52% 3.44TCr
+0.06%+0.34%+2.38%+34.47% 2.71TCr
+0.46%-3.49% - - 1.62TCr
-0.04%-0.09%+72.42%+116.45% 1.54TCr
+1.12%+1.91%+14.54%+15.44% 1.41TCr
0.00%+1.36%+18.43%-31.23% 1.3TCr
Average +0.88%+0.03%+65.98%+97.47% 2.71TCr
Weighted average by Cap. -0.03%-0.18%+79.44%+122.31%

Financials

2026 *2027 *
Net sales 60Cr 69Cr 55Cr 51Cr 96Cr 6.61TCr 98Cr 661.4Cr 260.14Cr 3.24TCr 257.7Cr 252.04Cr 11TCr 74Cr 84Cr 68Cr 63Cr 118.01Cr 8.11TCr 120.63Cr 811.9Cr 319.34Cr 3.97TCr 316.34Cr 309.4Cr 14TCr
Net income -15Cr -17Cr -14Cr -13Cr -24Cr -1.62TCr -24Cr -162.32Cr -64Cr -794.26Cr -63Cr -62Cr -2.73TCr -4.75Cr -5.43Cr -4.38Cr -4.04Cr -7.61Cr -522.94Cr -7.78Cr -52Cr -21Cr -256.12Cr -20Cr -20Cr -881.67Cr
Net Debt 4.15Cr 4.75Cr 3.83Cr 3.53Cr 6.65Cr 457.32Cr 6.8Cr 46Cr 18Cr 223.98Cr 18Cr 17Cr 771.03Cr 11Cr 12Cr 9.7Cr 8.95Cr 17Cr 1.16TCr 17Cr 115.99Cr 46Cr 567.59Cr 45Cr 44Cr 1.95TCr
Logo Evotec
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
3.440EUR
Average target price
4.900EUR
Spread / Average Target
+42.44%

Quarterly revenue - Rate of surprise